Highly potent inhibition of human immunodeficiency virus type 1 replication by TAK-220, an orally bioavailable small-molecule CCR5 antagonist.
about
TAK-220, a novel small-molecule CCR5 antagonist, has favorable anti-human immunodeficiency virus interactions with other antiretrovirals in vitro.TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humansPotent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1Closing the door to human immunodeficiency virus.Analysis of binding sites for the new small-molecule CCR5 antagonist TAK-220 on human CCR5.Inhibition of Inflammatory and Neuropathic Pain by Targeting a Mu Opioid Receptor/Chemokine Receptor5 Heteromer (MOR-CCR5).Design, synthesis and biological evaluation of novel piperazine derivatives as CCR5 antagonists.New approaches in the treatment of HIV/AIDS - focus on maraviroc and other CCR5 antagonistsThe novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100.CCR5 antagonists: the answer to inflammatory disease?Role of CXCR4 in HIV infection and its potential as a therapeutic target.Escape from human immunodeficiency virus type 1 (HIV-1) entry inhibitors.CCR5 inhibitors in HIV-1 therapy.Targeting CCR5 for anti-HIV research.Incompatible Natures of the HIV-1 Envelope in Resistance to the CCR5 Antagonist Cenicriviroc and to Neutralizing Antibodies.T-cell protection and enrichment through lentiviral CCR5 intrabody gene delivery.Isolation and characterization of human immunodeficiency virus type 1 resistant to the small-molecule CCR5 antagonist TAK-652.Bivalent ligand MCC22 potently attenuates nociception in a murine model of sickle cell disease.A guided tour through the antiviral drug field
P2860
Q24530591-2C38BD42-653B-4139-A6FA-A36CD8A50701Q24537285-1EC8D6E6-027C-479F-BB6A-8C17CA090BC3Q24673555-E39F2194-0B64-4EC6-8E40-917929B59BB7Q30428089-64914366-4F13-4903-A266-31A2A1F6087CQ34123627-13B3AD2B-197C-4460-A5A3-5335C2D5E2EDQ34497517-4C1F5D3B-09E9-4ABB-87A8-2A7A5E789257Q34545281-86D19F0C-C8FB-4F8B-8D73-B37BAD8739ABQ36823525-6B5DB100-8F55-476D-9CCE-B477DE7C2DC1Q37247686-9B9D6B31-DF66-43AE-9889-AEB1645FAC02Q37689783-185CCE7B-691F-4DE6-AC95-331E0294AC66Q37772888-752CF005-5129-4BD4-A076-1C54819AA718Q38076139-37E1DED4-C69D-4578-B6EB-559D5B2CEDEFQ38089881-1E77A982-F427-4F01-BA10-868888247699Q38229805-FE7B0559-8814-4B4D-9719-004973D4BD8EQ38822845-D5EA75AF-9227-4DA0-9B2B-4A50EA47F119Q39501413-268236E5-4982-44D8-82C0-ED7CBFAB001EQ42112291-10BA78B1-B133-4789-B8E2-F5B36A391ABCQ52316849-014B132D-B6F0-4F29-9FBE-C4017B696C91Q56786373-9E448222-F6CE-469A-9253-A2FB86273874
P2860
Highly potent inhibition of human immunodeficiency virus type 1 replication by TAK-220, an orally bioavailable small-molecule CCR5 antagonist.
description
2005 nî lūn-bûn
@nan
2005 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Highly potent inhibition of hu ...... mall-molecule CCR5 antagonist.
@ast
Highly potent inhibition of hu ...... mall-molecule CCR5 antagonist.
@en
type
label
Highly potent inhibition of hu ...... mall-molecule CCR5 antagonist.
@ast
Highly potent inhibition of hu ...... mall-molecule CCR5 antagonist.
@en
prefLabel
Highly potent inhibition of hu ...... mall-molecule CCR5 antagonist.
@ast
Highly potent inhibition of hu ...... mall-molecule CCR5 antagonist.
@en
P2093
P2860
P1476
Highly potent inhibition of hu ...... mall-molecule CCR5 antagonist.
@en
P2093
Hiroshi Miyake
Katsunori Takashima
Masanori Baba
Naoyuki Kanzaki
Yoshihiko Tagawa
Yoshihiro Sugihara
Yuji Iizawa
P2860
P304
P356
10.1128/AAC.49.8.3474-3482.2005
P407
P577
2005-08-01T00:00:00Z